Related Experiment Video
Updated: Jun 5, 2025
A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013
Designing a time-dependent therapeutic strategy using CDK4/6 inhibitors in an intracranial ATRT model
Brice Martin1, Sergio W Guadix1, Rekha Sathian2
1Department of Neurological Surgery, Weill Cornell Medicine, New York, New York, USA.
Background:
Inhibitors targeting cyclin-dependent kinases 4 and 6 (CDK4/6), crucial for cell cycle regulation, have shown promise in early-stage studies for treating central nervous system (CNS) tumors. However, challenges such as limited CNS penetration, optimal treatment duration, and systemic side effects have impeded their clinical translation for pediatric brain tumors (PBTs).
Methods:
We evaluated the potency of CDK4/6 inhibitors across various PBT cell lines, focusing particularly on palbociclib against atypical teratoid rhabdoid tumor (ATRT) with cell viability assays and gene expression analysis. Additionally, we assessed the efficacy and safety of intrathecal (IT) delivery of palbociclib through neurotoxicity and pharmacokinetic studies, along with survival assessments in murine leptomeningeal ATRT models.
Results:
Palbociclib showed the highest potency across various PBT cells, with extended treatments reducing growth inhibition 50 (GI50) values from the micromolar to nanomolar range. It suppressed critical cell cycle genes (CCNB1, CCNA2, CDK1) in BT16 ATRT cells. Neurotoxicity (GFAP, CD45, NeuN, Iba1) and pharmacokinetic assays confirmed IT route as a feasible and effective method for delivering palbociclib to the cerebrospinal fluid (CSF), avoiding systemic toxicity and enhancing drug concentration to the brain. Finally, metronomic IT delivery using an osmotic pump (OP, 48 mg/kg) increased survival in 2 murine leptomeningeal ATRT models, showcasing its potential as a novel therapy for leptomeningeal tumors.
Conclusions:
Metronomic IT delivery of palbociclib enhances drug efficacy and safety, improves survival, and offers a promising treatment strategy for PBTs with CSF dissemination.
Insights
Intrathecal palbociclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, shows promise for pediatric brain tumors (PBTs) with cerebrospinal fluid (CSF) spread. This novel delivery method enhances efficacy and survival in preclinical models.
Area of Science:
- Oncology
- Pharmacology
- Neuroscience
Background:
- Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show potential for central nervous system (CNS) tumors.
- Challenges include limited CNS penetration, treatment duration, and systemic toxicity for pediatric brain tumors (PBTs).
Purpose of the Study:
- To evaluate CDK4/6 inhibitors, specifically palbociclib, for PBTs.
- To assess the efficacy and safety of intrathecal (IT) palbociclib delivery.
- To investigate metronomic IT delivery for leptomeningeal PBT models.
Main Methods:
- Assessed palbociclib potency in PBT cell lines using viability and gene expression assays.
- Evaluated IT palbociclib delivery via neurotoxicity, pharmacokinetic, and survival studies in murine models.
- Utilized osmotic pumps for metronomic IT administration.
Main Results:
- Palbociclib demonstrated high potency against PBT cells, with extended treatment improving efficacy.
- IT delivery of palbociclib achieved effective cerebrospinal fluid (CSF) drug concentrations, avoiding systemic toxicity.
- Metronomic IT palbociclib significantly increased survival in leptomeningeal PBT models.
Conclusions:
- Metronomic intrathecal palbociclib is a promising strategy for PBTs with CSF dissemination.
- This approach enhances drug efficacy, safety, and patient survival.
- Further investigation into IT palbociclib for PBTs is warranted.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
